Q1 Revenue Surpasses Expectations with Growth in International Markets

Moderna (MRNA) reported Q1 revenue of $389 million, significantly exceeding market expectations. This represents a more than threefold increase compared to the same period last year. The decline in demand for its COVID-19 vaccine, Spikevax, in the U.S. market was offset by robust sales in international markets. In particular, the fulfillment of vaccine supply contracts and increased procurement in countries outside the U.S. have provided a foundation for stabilizing its financial structure. This demonstrates that global demand for the COVID-19 vaccine remains strong, even as the pandemic transitions into an endemic phase, particularly in certain regions.

One-Time Net Loss Increases Due to Patent Dispute Settlement

However, Moderna recorded a net loss of $1.3 billion in the quarter, an increase of approximately $1 billion compared to the same period last year. This loss reflects the impact of costs related to the litigation settlement with Arbutus Biopharma (ABUS) and Genevant Sciences concerning lipid nanoparticle (LNP) patents. As part of the global agreement between the parties, Moderna agreed to pay $950 million upfront and $1.3 billion contingent upon the outcome of appeals, for a total of up to $2.25 billion. Although this has a negative impact on short-term performance, it can be interpreted as a strategic decision to resolve long-term financial uncertainties by eliminating future royalty obligations related to vaccine sales.

Successful Cost Reduction and Improved Operational Efficiency

Excluding the one-time settlement costs, Moderna has successfully continued its efforts to improve operational efficiency by significantly reducing selling, general, and administrative (SG&A) expenses and research and development (R&D) expenditures. R&D expenses in the first quarter decreased by 24% year-over-year to $649 million, and SG&A expenses also decreased by 18% to $173 million. This is the result of proactive restructuring and fixed cost reductions in response to the end of government subsidies and the decline in vaccine sales. This efficient cash management is expected to serve as a key foundation for supporting the development of next-generation pipelines.

Next-Generation Pipeline and Diversified Growth Momentum

The primary reason investors are paying attention to Moderna is its next-generation portfolio beyond the COVID-19 vaccine. mRNA-4157 (V940), a personalized neoantigen therapy co-developed with Merck (MRK), is expected to release Phase 3 results for the treatment of melanoma this year. In addition, mCOMBRIAX (mRNA-1083), a combination vaccine for influenza and COVID-19 that has received approval from the European Commission (EC), and mRNA-1010, an influenza vaccine with a Prescription Drug User Fee Act (PDUFA) date of August 5, are expected to drive commercial growth in the future, providing significant growth momentum.